

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**開拓藥業有限公司 \***  
**KINTOR PHARMACEUTICAL LIMITED**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 9939)**

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF  
BUSINESS IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of Kintor Pharmaceutical Limited (the “**Company**”) hereby announces that, the principal place of business in Hong Kong of the Company will be changed to 40th Floor, Dah Sing Financial Centre, No.248 Queen’s Road East, Wanchai, Hong Kong, with effect from 1 November 2024. The telephone number, email address and website of the Company will remain unchanged.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**  
**Dr. Youzhi Tong**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 16 October 2024

*As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

*\* For identification purpose only*